Loading...
•
Nov 30, 2025
Nurix Q4 2025 Earnings Report
Nurix reported a wider net loss in Q4 2025 despite stable revenue, driven by higher R&D expenses.
Key Takeaways
Nurix Therapeutics posted a net loss of $78.2 million in Q4 2025, with revenue holding steady at $13.6 million. Increased R&D spending contributed to the broader loss, while the company ended the quarter with strong liquidity.
Q4 revenue was $13.6 million, slightly above the prior year’s $13.3 million.
Net loss widened to $78.2 million due to increased R&D expenses.
EPS for the quarter was ($0.82), compared to ($0.75) in Q4 2024.
Cash and marketable securities totaled $592.9 million at quarter end.
Revenue by Segment
Forward Guidance
Nurix plans to continue pivotal and confirmatory trials for bexobrutideg in CLL and expand into autoimmune indications.
Positive Outlook
- DAYBreak Phase 2 trial for bexobrutideg is underway targeting relapsed/refractory CLL.
- Planned Phase 3 confirmatory trial to support full approval in H1 2026.
- Encouraging Phase 1 data in Waldenström macroglobulinemia supports broader BTK targeting.
- Clinical pipeline includes multiple first-in-class degraders and checkpoint therapies.
- Strong financial position with $592.9 million in cash and marketable securities.
Challenges Ahead
- Increased R&D expenses widened net loss in Q4.
- No GAAP or non-GAAP profitability expected in near-term.
- High operating expenses could continue impacting margins.
- Dependence on collaboration milestones and licensing revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...